Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab discontinuation in early Crohn's disease (CURE)
NCT03306446Phase 4Unknown
- Sponsor
- GETAID
- Start
- Mar 2015
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of adalimumab in Crohn's disease, sponsored by GETAID. Status: unknown.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03306446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306446.